JP2023551734A - 眼の疾患を治療するための組成物及び方法 - Google Patents

眼の疾患を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2023551734A
JP2023551734A JP2023533830A JP2023533830A JP2023551734A JP 2023551734 A JP2023551734 A JP 2023551734A JP 2023533830 A JP2023533830 A JP 2023533830A JP 2023533830 A JP2023533830 A JP 2023533830A JP 2023551734 A JP2023551734 A JP 2023551734A
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
faba
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533830A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022120137A5 (https=
JP2023551734A5 (https=
Inventor
グローバー，アニタ
テイラー，ロリ
イェドノック，テッド
Original Assignee
アネクソン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アネクソン，インコーポレーテッド filed Critical アネクソン，インコーポレーテッド
Publication of JP2023551734A publication Critical patent/JP2023551734A/ja
Publication of JPWO2022120137A5 publication Critical patent/JPWO2022120137A5/ja
Publication of JP2023551734A5 publication Critical patent/JP2023551734A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023533830A 2020-12-04 2021-12-03 眼の疾患を治療するための組成物及び方法 Pending JP2023551734A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121629P 2020-12-04 2020-12-04
US63/121,629 2020-12-04
PCT/US2021/061755 WO2022120137A1 (en) 2020-12-04 2021-12-03 Compositions and methods for treating ocular diseases

Publications (3)

Publication Number Publication Date
JP2023551734A true JP2023551734A (ja) 2023-12-12
JPWO2022120137A5 JPWO2022120137A5 (https=) 2024-12-10
JP2023551734A5 JP2023551734A5 (https=) 2024-12-10

Family

ID=81853584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533830A Pending JP2023551734A (ja) 2020-12-04 2021-12-03 眼の疾患を治療するための組成物及び方法

Country Status (11)

Country Link
US (1) US20240059765A1 (https=)
EP (1) EP4255485A4 (https=)
JP (1) JP2023551734A (https=)
KR (1) KR20230117192A (https=)
CN (1) CN116782940A (https=)
AU (1) AU2021391800A1 (https=)
CA (1) CA3200976A1 (https=)
CL (1) CL2023001596A1 (https=)
IL (1) IL303289A (https=)
MX (1) MX2023006591A (https=)
WO (1) WO2022120137A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
KR20250006238A (ko) * 2022-04-29 2025-01-10 애넥슨, 인코포레이티드 안구 질환을 치료하기 위한 조성물 및 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526393A (ja) * 2013-07-09 2016-09-05 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
JP2019501132A (ja) * 2015-11-24 2019-01-17 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ Ｆａｂ断片及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526393A (ja) * 2013-07-09 2016-09-05 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
JP2019501132A (ja) * 2015-11-24 2019-01-17 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ Ｆａｂ断片及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLECULAR NEURODEGENERATION, vol. 13, no. 1, JPN6025045722, 2018, ISSN: 0005728343 *

Also Published As

Publication number Publication date
AU2021391800A1 (en) 2023-06-22
CN116782940A (zh) 2023-09-19
CL2023001596A1 (es) 2024-01-19
EP4255485A4 (en) 2025-05-14
KR20230117192A (ko) 2023-08-07
US20240059765A1 (en) 2024-02-22
CA3200976A1 (en) 2022-06-09
EP4255485A1 (en) 2023-10-11
MX2023006591A (es) 2023-08-11
WO2022120137A1 (en) 2022-06-09
IL303289A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
US20250002567A1 (en) Anti-complement factor c1q fab fragments and uses thereof
AU2007329759B2 (en) Compositions and methods for binding sphingosine-1-phosphate
JP5732182B2 (ja) 眼疾患と症状を処置するための組成物および方法
JP2023551734A (ja) 眼の疾患を治療するための組成物及び方法
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
IL296528A (en) Tie2-binding agents and methods of use
JP2020519634A (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
KR20190005944A (ko) 척수성 근위축 치료용 조성물 및 방법
CA3030872A1 (en) Compositions and methods for treating frontotemporal dementia
US20230159637A1 (en) Methods of use of anti-trem2 antibodies
US20250313614A1 (en) Compositions and methods for treating ocular diseases
EA050212B1 (ru) Композиции и способы лечения болезней глаз
HK40101076A (zh) 用於治疗眼部疾病的组合物和方法
HK40121733A (zh) 用於治疗眼部疾病的组合物和方法
CA3006092C (en) Anti-complement factor c1q fab fragments and uses thereof
AU2013273727A1 (en) Compositions and methods for treating ocular diseases and conditions
AU2016204486A1 (en) Composition and Methods for Treating Ocular Diseases and Conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230825

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210